Antiplatelet Therapy In Ckd

Authors

  • Pradip Kumar Dutta Professor of Nephrology, Chittagong Medical College, Chittagong, Bangladesh
  • Arup Dutta Associate Professor of Paediatrics, Cox's Bazar Medical College, Cox's Bazar, Bangladesh

DOI:

https://doi.org/10.3329/jcmcta.v24i1.57755

Keywords:

Antiplatelet agents; cardiovascular events; CKD

Abstract

Chronic kidney disease (CKD) patients are at increased risk of cardiovascular events (CVE) than general population. Antiplatelet agents (APA) reduce CVE in patients with normal kidney function. Whether they are of same efficacy and safety in CKD population is questionable because most of the studies did not include CKD population in their trial of APAs. At one hand there is poor response to APAs because of altered metabolism, on the other hand there is paradoxical more risk of major bleeding. This review will, address these issues of APAs use in CKD.

JCMCTA 2013; 24 (1):70-75

Downloads

Download data is not yet available.
Abstract
41
PDF
43

Downloads

Published

2013-09-14

How to Cite

Dutta, P. K. ., & Dutta, A. . (2013). Antiplatelet Therapy In Ckd. Journal of Chittagong Medical College Teachers’ Association, 24(1), 70–75. https://doi.org/10.3329/jcmcta.v24i1.57755

Issue

Vol. 24 No. 1 (2013)

Section

Review